Premium
Chondrosarcoma local recurrence in the Cancer Registry of Norway cohort (1990–2013): Patterns and impact
Author(s) -
Thorkildsen Joachim,
Norum OleJacob,
Myklebust Tor A.,
Zaikova Olga
Publication year - 2021
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.26308
Subject(s) - medicine , hazard ratio , chondrosarcoma , proportional hazards model , curettage , metastasis , confidence interval , malignancy , cancer registry , cancer , surgery , cohort , intramedullary rod , oncology , asymptomatic
Background There appears to be an association between local recurrence (LR) and risk of metastasis and death in central conventional chondrosarcoma (CCCS) of bone, but this has not been quantified in modern cohorts at a subtype level. Methods We identified nonmetastatic cases of CCCS ( N = 180) from the Cancer Registry of Norway. We present prognostic analysis of LR accounting for immortal time bias by descriptive statistics and multivariable Cox models. Results Of 40 LR, one case demonstrated upgrading while two dedifferentiation. LR was associated with increased risk of metastasis (hazard ratio [HR] = 4.1 [confidence interval, 1.5–10.7]) and death (HR = 9.3 [5.0–17.5]) overall. LR was associated with significant increased risk of metastasis for those with a soft tissue component, axial location, malignancy grade 2, but not atypical cartilaginous tumor's, appropriately treated curettage patients, intramedullary tumors, grade 1 histology, extremity location or “Oslo low risk” group status. We found an increased risk of death for all groups except for those treated by appropriate curettage or belonging to the “Oslo low risk” group. About 50% of LR CCCS were asymptomatic and revealed by routine follow‐up. Conclusions Upgrading of LR for CCCS was a seldom event. LR was associated with significant increased risk of metastasis and death overall, but not for appropriately treated curettage patients or “Oslo low risk” status.